Medical Device Regulatory Consulting Services

In the United States, the Food and Drug Administration (FDA) is the primary regulatory agency overseeing medical devices under 21 CFR. Internationally, key bodies include the European Medicines Agency (EMA) under EU MDR, Health Canada, Japan's PMDA, and the TGA in Australia. Manufacturers distributing globally must comply with each relevant authority's specific submission, labeling, and post-market requirements.

Quality Assurance (QA) focuses on the internal processes, systems, and controls that ensure a medical device consistently meets defined quality standards — such as ISO 13485 compliance and GMP practices. Regulatory Affairs (RA) focuses on the external relationship with regulatory agencies, managing submissions, approvals, labeling requirements, and ongoing compliance with laws like 21 CFR. Both functions are essential and closely interconnected for medical device companies.

21 CFR (Code of Federal Regulations, Title 21) is the section of U.S. federal law that governs food, drugs, and medical devices regulated by the FDA. For medical devices specifically, Part 820 covers Quality System Regulations (QSR), Part 801 covers labeling, and Part 807 covers pre-market notification (510(k)) requirements. Compliance with applicable 21 CFR parts is mandatory for legally marketing medical devices in the U.S.

Medical device regulatory refers to the framework of laws, standards, and agency guidelines that govern how medical devices are designed, manufactured, labeled, distributed, and monitored post-market. It encompasses FDA submissions, ISO certifications, GMP practices, labeling standards, and international compliance requirements. Regulatory consulting helps businesses navigate these complex requirements efficiently, reducing the risk of delays, recalls, or enforcement actions.

Regulatory consulting fees vary based on project scope, device classification, and the complexity of the regulatory pathway involved. Hourly rates typically range from $150 to $400 per hour, while project-based engagements for full submissions or quality system builds can range from $5,000 to $50,000 or more. At Bluebonnet, we work to provide transparent, customized pricing that fits your specific project needs and budget.

21 CFR Part 820 is the FDA's Quality System Regulation (QSR) for medical device manufacturers in the U.S., while ISO 13485 is an internationally recognized quality management standard. Both address quality system requirements but differ in scope and enforcement — 21 CFR 820 is a U.S. legal requirement enforced by the FDA, while ISO 13485 certification is globally recognized and often required for market access in the EU, Canada, and other international markets.

FDA review timelines vary by submission type. A standard 510(k) pre-market notification typically takes 90 to 150 days for FDA review, though preparation time can add several months. De Novo requests may take 150 days or longer. PMA applications for high-risk Class III devices can take one year or more. Thorough, well-prepared submissions with complete documentation can significantly reduce back-and-forth and shorten overall timelines.

Yes. Regulatory obligations don't end at market clearance. Medical device companies must maintain post-market surveillance, submit MDR reports for adverse events, manage labeling changes, track design modifications that may require new submissions, and keep quality management system records current. Regular regulatory audits and ongoing compliance monitoring are critical to avoiding enforcement actions, warning letters, or product recalls after a device is on the market.